Vitamin K2 (bones).
Supports bone health and calcium utilization. Acts like a GPS for calcium. It activates proteins that help bind calcium to your bones.
Reviewed March 2026
- Category
- Vitamin
- Also filed under
- Bone HealthCardiovascular HealthCalcium Regulation
What Vitamin K2 (Bones) is, and what it does.
- Does it work
- Yes, especially if you take Vitamin D and care about bone health. It makes sure the calcium you get is actually used properly.
- How much to take
- 100-200 mcg per day. Look for the MK-7 form, it lasts longer in your body than MK-4.
- Time to feel it
- Carboxylation markers respond across four to twelve weeks. Bone density itself is measured over a year or more, so this one shows up on a scan rather than in your day.
- The first dose
- Absolutely nothing. This is a long game for structural health.
- With regular use
- The goal is healthier bones and clearer arteries over decades. You won't see it, but your bone density scan might.
- How well tolerated
- Well tolerated for most people. The big exception is for those on blood thinners. You must clear it with your doctor first.
- How it feels
- You don't feel it. It's silent infrastructure work for your skeleton and arteries.
- The overlooked benefit
- Vitamin D turns up osteocalcin production while vitamin K supplies the carboxylation that makes that protein able to bind calcium. The pair is really one step and a half.
100mcg a day is where Vitamin K2 (Bones) works.
Source: Knapen 2013 + Geleijnse 2004 Rotterdam study
The proof, claim by claim.
What these words mean
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
There's reasonable evidence supporting Vitamin K2's role in bone health and calcium metabolism, particularly in specific populations. Studies suggest benefits, but the effects can be subtle and require consistent intake over time. It's not a dramatic effect, but a worthwhile contribution, especially when paired with Vitamin D3.
- osteocalcin carboxylation statusRandomised trial
- bone mineral density maintenanceMeta-analysis
2 more claims
- matrix Gla protein activationRandomised trial
- longer circulating half-life of MK-7 than MK-4Randomised trial
Questions people ask about Vitamin K2 (Bones).
- What's the difference between Vitamin K1 and K2?
- K1 is mostly for blood clotting and comes from leafy greens. K2 is for calcium placement and comes from fermented foods or animal products.
5 more questions
- Do I need this if I take Vitamin D?
- It's a very good idea. Vitamin D helps you absorb calcium, and K2 helps direct that calcium to your bones instead of your arteries.
- Is MK-7 or MK-4 better?
- MK-7 is generally better. It stays active in your body for much longer, so you can take it once a day.
- Can I get enough from my diet?
- It's tough unless you eat natto (fermented soybeans) regularly. Cheeses and egg yolks have some, but often not enough.
- Does this really help my heart?
- The evidence is promising. By keeping calcium out of artery walls, it may help maintain flexibility and blood flow over the long term.
- What time of day should I take it?
- Take it with a meal that has some fat in it. K2 is fat-soluble, so this helps your body absorb it.
Why these belong in the same formula, 22 pairings
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Vitamin D raises transcription of osteocalcin and matrix Gla protein, and vitamin K2 carboxylates those same proteins so they can bind calcium. One makes the protein, the other switches it on.
Carboxylated matrix Gla protein and osteocalcin are what steer calcium into bone matrix rather than into vessel wall and soft tissue. K2 therefore governs where a calcium dose ends up.
Magnesium is the cofactor for the hydroxylases that convert vitamin D to its active form, so it sits upstream of the K2 substrate supply. It is also a structural ion in the mineral that K2-dependent proteins help lay down.
The vitamin D receptor works as a heterodimer with the retinoid X receptor on the osteocalcin gene, so retinoid status shapes how much osteocalcin is made. K2 then carboxylates whatever is produced.
Large intakes of alpha-tocopherol interfere with the vitamin K quinone cycle and with gamma-carboxylation. A high vitamin E dose in the same formula can therefore work against K2 activity and normal clotting factor carboxylation.
Menaquinones are fat soluble and need lipid in the gut to form the micelles they travel in. A lipid carrier or a meal raises how much of the dose is taken up.
K1 and K2 feed the same carboxylase and the same quinone recycling cycle, and tissues convert part of a K1 dose into menaquinone-4. The two overlap rather than act as separate nutrients.
Alkaline phosphatase, the enzyme that prepares phosphate for mineral deposition, is a zinc metalloenzyme. Zinc therefore serves the deposition step that K2-dependent osteocalcin regulates.
Ascorbate is the cofactor for the prolyl and lysyl hydroxylases that build the collagen scaffold bone mineral deposits onto. K2 governs the mineral, vitamin C the matrix underneath it.
Bone is a collagen matrix that is then mineralised, and the covalent crosslinks holding that matrix together are formed by lysyl oxidase with copper at its active site. Menaquinone acts on the other side of the same matrix, carboxylating osteocalcin so it can bind calcium. The two support different steps of matrix quality and are commonly formulated together.
Manganese is the cofactor for the glycosyltransferases that assemble glycosaminoglycans in connective tissue and bone ground substance. Vitamin K2 contributes the carboxylation step that lets osteocalcin and matrix Gla protein bind calcium. Both feed the matrix side of bone, from different enzymes.
Boron affects how the body handles calcium and magnesium and appears at low levels in bone-support formulas for that reason. Vitamin K2 works on the carboxylation of bone matrix proteins rather than on mineral handling. The two are complementary in a formula rather than chemically interacting.
Silicon is found where new bone matrix meets mineral and is associated with connective tissue formation, though no specific human enzyme requiring it has been identified. Vitamin K2 carboxylates osteocalcin, one of the most abundant non-collagen proteins in that same matrix. They are paired on shared location in the tissue, not on a combination trial.
Roughly ninety percent of the organic matrix of bone is type I collagen, and osteocalcin is deposited into it. Carboxylated osteocalcin then binds calcium in the hydroxyapatite that forms around that scaffold. Supplying collagen substrate and the carboxylation cofactor addresses two ends of the same structure.
Bone mineral is calcium phosphate laid down as hydroxyapatite, so phosphate availability is part of the mineralisation account alongside calcium. Vitamin K2 carboxylates the Gla residues that bind that calcium. This is lattice chemistry, and it is not a claim about any measured endpoint.
MK-7 has a long isoprenoid tail and is strongly lipophilic, so it needs dietary fat and bile-driven micelle formation to be absorbed. An oil vehicle in a softgel, or fat in the accompanying meal, supplies that. This is a delivery relationship and applies to any long-chain oil.
Long-chain omega-3 triglycerides and menaquinone both enter mixed micelles and are packaged into chylomicrons, which is why K2 is often filled into an omega-3 softgel. The oil supplies the lipid phase that the vitamin needs. Co-formulation is a delivery choice, not an additive effect.
Menaquinone and ubiquinone share a naphthoquinone or benzoquinone head with a polyisoprenoid tail assembled from geranylgeranyl and farnesyl diphosphate units off the mevalonate pathway. That shared origin is why drugs that block the mevalonate pathway lower both. In a formula they are separately dosed lipophilic quinones with a common biosynthetic ancestry.
Natto fermentation produces both the long-chain menaquinone MK-7 and the fibrinolytic enzyme nattokinase, so the two often arrive from the same production stream. Some nattokinase preparations are deliberately K2-depleted and some are not, which matters for anyone counting total K intake. Read the pairing as a shared origin rather than a mechanistic synergy.
Members of the colonic microbiota, particularly Bacteroides and some lactic acid bacteria, produce menaquinones with side chains of varying length as part of their own respiration. How much of that colonic pool is absorbed by the host is debated, since absorption there is limited without bile. The relationship is a source one, and its size in humans is not settled.
Menaquinone output differs sharply between gut species, so the composition of the microbiota shapes how much is made in the colon. Bifidobacteria contribute to that community and to the fermentation environment around it. Any host contribution from this route is uncertain and should not be counted as a dose.
The vitamin K cycle depends on reducing equivalents to convert the epoxide back to the active hydroquinone, and NAD(P)H-dependent quinone reductases sit in that loop with flavin cofactors derived from riboflavin. This connects riboflavin status to the recycling capacity of vitamin K rather than to how much is absorbed. State it as mechanistic.
Talk to a doctor before taking Vitamin K2 (Bones) if any of these apply to you: Individuals on blood thinners (anticoagulants) should consult with their doctor, as Vitamin K can affect blood clotting, Those with kidney issues should consult their doctor. These are flags to check first, not effects Vitamin K2 (Bones) is known to cause.
Not medical advice. Show the label to your pharmacist.What Vitamin K2 (Bones) actually does.
Menaquinone helps an enzyme add an extra chemical group to specific proteins, including one in bone, giving them the ability to grab onto calcium.
3 more mechanisms
That reaction uses up a form of vitamin K and leaves behind a spent version, which another enzyme recycles, so a small store of vitamin K gets reused many times over.
A protein that has not had that extra group added binds calcium poorly, so the ratio of the unmodified to the modified form is used as a marker of vitamin K status, not a direct measure of bone strength.
MK-7, one form of K2, is more fat-soluble than MK-4 and stays in the blood far longer, days instead of hours after a single dose.
Where Vitamin K2 (Bones) comes from.
MK-7 is made by fermenting soybeans or chickpeas with the same bacterium that makes natto, then pulling the vitamin out and cleaning it up. MK-4 is built chemically instead. Either way it ends up suspended in oil or coated in a powder so it survives in a tablet.
What this route gives you
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
6 steps on record
The fermentation route steams whole legumes as the substrate. The semi-synthetic MK-4 route starts instead from menadione and geranylgeraniol.
In fermentation, a selected Bacillus subtilis natto strain grows on the substrate and secretes MK-7 as part of its respiratory chain over a controlled multi-day cycle. In the synthetic route, the isoprenoid side chain is attached to the quinone head chemically.
The menaquinone is taken up from the biomass with a food-grade solvent, then the solvent is stripped under vacuum at low temperature because the molecule is light and heat sensitive.
Purification separates MK-7 from other chain lengths and from the cis isomer, which has no biological activity. All-trans percentage is the specification that matters most here.
Purified material is assayed by high-performance liquid chromatography and diluted onto an oil or a dry carrier to a declared microgram-per-gram potency.
Filled into softgels and drops as an oil suspension, or spray-dried into a protective matrix for tablets and dry blends where alkaline minerals would otherwise degrade it.
Getting Vitamin K2 (Bones) from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
4 more forms
The essence, in one line each.
- Six months of vitamin K supplementation did not detectably slow arterial calcification progression or bone density decline in adults with a diagnosed blood-sugar condition and a history of a diagnosed cardiovascular condition.Randomised trial, in patients with DM2 and CVD. Bartstra et al., 2021 (European Journal of Nutrition). PMID 33068157 β
5 more findings
- Primary human osteoblasts from donors with reduced bone density showed greater osteogenic differentiation on a roughened titanium surface with vitamin K2 present. A cell-culture marker result, not a clinical outcome.In vitro study. Tscheu et al., 2026 (Journal of Functional Biomaterials). PMID 42346679 β
- A mechanistic review of vitamin D and K2 in cardiometabolic risk that separates the pharmacological rationale from what supplementation has actually shown.Narrative review. D'Elia et al., 2025 (International Journal of Molecular Sciences). PMID 41516172 β
- A review of nutritional factors in bone integration around implants, naming vitamin K among the nutrients relevant to matrix protein carboxylation.Narrative review. Wnuk-Scardaccione et al., 2025 (Nutrients). PMID 40004935 β
- A wide narrative review of multivitamin and multimineral supplementation that names vitamin K2 among the nutrients covered. It summarises rather than tests.Narrative review. Nawathe et al., 2026 (Cureus). PMID 42220661 β
- A narrative review of nutritional supplements studied in ageing populations, listing vitamin K among the nutrients reviewed. No single-nutrient conclusion is drawn.Narrative review. Fekete et al., 2023 (Nutrients). PMID 38140375 β
Chosen from the 8 we read for Vitamin K2 (Bones).
The studies, linked.
12 sources behind our Vitamin K2 (Bones) verdict, every one linked to PubMed, the journal or ClinicalTrials.gov.
- Meta-analysisThe Effect of Calcium or Calcium and Vitamin D Supplementation on Bone Mineral Density in Healthy Males: A Systematic Review and Meta-Analysis.PubMed βInternational journal of sport nutrition and exercise metabolism, 2015, cited 32 times
11 more linked trials
- ReviewScreening for Vitamin D Deficiency: A Systematic Review for the U.S. Preventive Services Task ForcePubMed βAnnals of Internal Medicine, 2015, cited 126 times
- ReviewBones of Contention: Bone Mineral Density Recovery in Celiac DiseaseβA Systematic ReviewPubMed βNutrients, 2015, cited 73 times, open access
- ReviewHigh-Dose Vitamin D and Calcium Attenuates Bone Loss with Antiretroviral Therapy InitiationPubMed βAnnals of internal medicine, 2015, cited 61 times, open access
- ReviewProper Calcium Use: Vitamin K2 as a Promoter of Bone and Cardiovascular Health.PubMed βIntegrative medicine, 2015, cited 57 times
- PubMed β
- StudyA 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosusPubMed βLupus, 2015, cited 73 times
- StudyRole of vitamin D levels and vitamin D supplementation on bone mineral density in Klinefelter syndromePubMed βOsteoporosis International, 2015, cited 59 times
- StudyVITALITY trial: protocol for a randomised controlled trial to establish the role of postnatal vitamin D supplementation in infant immune healthPubMed βBMJ Open, 2015, cited 54 times, open access
- StudyCost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis.PubMed βEuropean journal of public health, 2015, cited 45 times, open access
- StudyAre Growing Pains Related to Vitamin D Deficiency? Efficacy of Vitamin D Therapy for Resolution of SymptomsPubMed βMedical Principles and Practice, 2015, cited 41 times, open access
- StudyConsumption of vitamin D2 enhanced mushrooms is associated with improved bone health.PubMed βThe Journal of nutritional biochemistry, 2015, cited 36 times, open access
From clinical trials and PubMed, ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.